Adenosine can mediate the tubuloglomerular (TGF) response via activation of A1 receptors on the afferent arteriole, but both adenosine A1 and A2 receptors can regulate preglomerular resistance. We tested the hypothesis that adenosine A2 receptors offset the effect of A1 receptors and modulate the TGF. Maximal TGF responses were measured in male Sprague-Dawley rats as changes in proximal stop-flow pressure (⌬PSF) in response to increased perfusion of the loop of Henle (0 to 40 nl/min) with artificial tubular fluid (ATF). The maximal TGF response was studied after 5 min of intratubular perfusion (10 nl/min) with ATF alone, or with ATF plus the A2A receptor antagonist (ZM-241385; 10 Ϫ7 or 10 Ϫ5 mol/l), A1 receptor antagonist (PSB-36; 10 Ϫ8 mol/l), or with a combination of A1 10 Ϫ8 mol/l) and A2A (ZM-241385; 10 Ϫ7 mol/l) antagonists. The maximal TGF response (⌬PSF) with ATF alone was 11.7 Ϯ 1.0 mmHg. Specific A2 inhibition (low dose) enhanced the maximal TGF response (15.7 Ϯ 0.8 mmHg; P Ͻ 0.01), whereas a high dose (unspecific inhibition) attenuated the response (5.0 Ϯ 0.4 mmHg; P Ͻ 0.001). A1 inhibition alone led to a paradoxical TGF response, with an increase in PSF of 3.1 Ϯ 0.5 mmHg (P Ͻ 0.05). Simultaneous application of A1 and A2 antagonists abolished the TGF response (⌬PSF: 0.4 Ϯ 0.3 mmHg). In conclusion, adenosine A2 receptors modulate the TGF response by counteracting the effects of adenosine A1 receptors. adenosine receptors; kidney; micropuncture; renal microcirculation ADENOSINE IS AN ENDOGENOUS purine nucleoside that modulates kidney function. Cellular signaling by adenosine occurs through G protein-coupled receptor subtypes (i.e., A 1 , A 2 , and A 3 ). The adenosine A 2 receptor family consists of two subtypes, A 2A and the A 2B , which possess a high and a low agonist affinity, respectively (33). Adenylate cyclase, thus cAMP production, is stimulated by the adenosine A 2A and A 2B receptors but inhibited by A 1 and A 3 receptors (33). Extracellular adenosine can derive from cellular adenosine release or by extracellular breakdown of ATP, AMP, or cAMP and is generated at enhanced rates when tubular NaCl reabsorption is increased (33). The tubuloglomerular feedback (TGF) mechanism is a negative feedback loop that senses changes in luminal NaCl delivery at the macula densa in the juxtaglomerular apparatus and adjusts the vascular tone of the afferent arteriole accordingly (28). Osswald and coworkers (20) first proposed that local generation of adenosine, as a consequence of increased NaCl transport, may elicit TGF-induced afferent arteriole vasoconstriction. The TGF mechanism contributes to the kidney's ability to regulate renal microcirculation, fluid homeostasis, and, consequently, blood pressure. Adenosine, via activation of A 1 receptors, has been demonstrated to mediate the TGF response in both rats (8, 29) and mice (4, 30), whereas angiotensin II, nitric oxide, and superoxide have important roles in modulating the response (32, 35) . ATP has been shown to mediate vasoconstriction of preglomerular vessels via P2X 1 receptor activation, thus contributing to autoregulatory behavior of the kidney (12). During the last years, it has been debated whether that released ATP acts directly through stimulation of P2 receptors or if it is hydrolyzed to adenosine, which evokes TGF responses through activation of A 1 receptors (11, 27) .
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The tubuloglomerular feedback (TGF) mechanism is a negative feedback loop that senses changes in luminal NaCl delivery at the macula densa in the juxtaglomerular apparatus and adjusts the vascular tone of the afferent arteriole accordingly (28) . Osswald and coworkers (20) first proposed that local generation of adenosine, as a consequence of increased NaCl transport, may elicit TGF-induced afferent arteriole vasoconstriction. The TGF mechanism contributes to the kidney's ability to regulate renal microcirculation, fluid homeostasis, and, consequently, blood pressure. Adenosine, via activation of A 1 receptors, has been demonstrated to mediate the TGF response in both rats (8, 29) and mice (4, 30) , whereas angiotensin II, nitric oxide, and superoxide have important roles in modulating the response (32, 35) . ATP has been shown to mediate vasoconstriction of preglomerular vessels via P2X 1 receptor activation, thus contributing to autoregulatory behavior of the kidney (12) . During the last years, it has been debated whether that released ATP acts directly through stimulation of P2 receptors or if it is hydrolyzed to adenosine, which evokes TGF responses through activation of A 1 receptors (11, 27) .
Both adenosine A 1 and A 2 receptors are expressed in renal afferent arterioles and can regulate preglomerular resistance (13, 33, 34) . Adenosine A 1 receptors mediate constriction, and A 2 receptors mediate dilatation of the afferent arteriole (10, 17) . However, the role of A 2 receptors in modulating the TGF response has not been established. Therefore, we tested the hypothesis that activation of A 2 receptors may counteract A 1 -mediated contraction and dampen the TGF response.
MATERIALS AND METHODS
Animals. This study was approved by the Georgetown University Animal Care and Use Committee and performed according to the National Institutes of Health guidelines for the conduct of experiments in animals. Male Sprague-Dawley rats (Charles River Laboratories International) weighing 250 -350 g were maintained on a standard rat chow (0.3 g sodium/100 g content) with free access to food and tap water until the day of the study.
Surgical preparation. On the day of the experiment, the rats were anesthetized by an intraperitoneal injection of thiobarbital (Inactin, 120 mg/kg body wt; Research Biochemicals, Natick, MA). The animals were placed on a servo-regulated heating pad with a rectal probe to maintain their body temperature at 37°C. The trachea was cannulated to allow spontaneous breathing. Catheters were placed in the left jugular vein for infusion of maintenance fluid (0.9% NaCl; 5 ml·h Ϫ1 ·kg body wt Ϫ1 ) and in the right femoral artery for the recording of mean arterial pressure (MAP). The bladder and the left ureter were cannulated to ensure unrestricted urine flow. The left kidney was exposed by a flank incision, cleaned from surrounding tissue, stabilized in a Lucite cup without stretching the renal vessels, and bathed in 0.9% NaCl solution maintained at 37°C. Micropuncture experiments were initiated after a 30-to 40-min stabilization period.
TGF experiments. TGF was determined by the stop-flow technique. Under a stereomicroscope, randomly chosen proximal tubular segments on the kidney surface were punctured with a sharpened micropipette (7-9 m OD) containing artificial tubular fluid (ATF; in mM: 128 NaCl, 4 NaHCO 3, 5 KCl, 2 CaCl2, 7 urea, and 2 MgCl2, pH 7.4) stained with Lissamine green dye (2 g/l) to identify the nephron and the direction of the tubular flow. Subsequently, grease (T grade; Apiezon, Manchester, UK) was inserted in the micropuncture site with a micropipette (7-9 m OD) connected to a hydraulic drive (Trent Wells, La Jolla, CA) to halt tubular flow. A perfusion pipette containing ATF with testing compounds or vehicle was inserted in the late proximal tubule downstream from the grease block and connected to a nanoliter microperfusion pump (Vestavia Scientific, Birmingham, AL). A pressure pipette (3-5 m OD) was inserted in the proximal tubule upstream from the grease block to measure proximal stop-flow pressure (P SF) or in unobstructed nephrons to determine proximal free-flow pressure (PFF). The micropressure system (model 900A; World Precision Instruments, Sarasota, FL) was connected to a Powerlab (AD Instruments, Colorado Springs, CO) to record MAP, P FF, and PSF.
Study design. The maximal TGF response for each nephron was assessed by the difference in P SF at zero loop perfusion and during perfusion at 40 nl/min (for 2 min). The adenosine receptor antagonists were dissolved in dimethyl sulfoxide (DMSO) and added to ATF (1% DMSO). The stop-flow measurements were taken before and after 5 min of intratubular administration at a low, non-TGF-activating perfusion rate (i.e., 10 nl/min).
The following protocols were employed: protocol 1, A 2A receptor antagonist (ZM-241385; 10 Ϫ7 mol/l); protocol 2, A2A receptor antagonist (ZM-241385; 10 Ϫ5 mol/l); protocol 3, A1 receptor antagonist (PSB-36; 10 Ϫ8 mol/l); and protocol 4, A1 ϩ A2A receptor antagonists (PSB-36; 10
, purchased from Tocris Bioscience (Ellisville, MO), is a potent and highly selective A 2A adenosine antagonist and is active in vivo (9, 15, 18, 21) . It has binding affinities of 540, 1.4, 31, and 270 nM for human (h) A 1, hA2A, hA2B, hA3 receptors, respectively, and shows selectivities of 1,000, 91, and 500,000 over A1, A2B, and A3 sites (16) . Thus the lower dose of ZM-241385 used in the present study (i.e., 10 Ϫ7 mol/l) may inhibit both A2A and A2B receptors, but not A1 and A3 receptors. The high dose, however, is nonspecific and may affect all four adenosine receptors.
Tocris Bioscience, is a potent and selective A 1 adenosine receptor antagonist and is active in vivo (1, 3) . It has binding affinities of 0.12, 552, 187, and 6,500 nM for rat (r) A 1, rA2A, hA2B, and rA3 receptors, respectively (1) . Thus, at the concentration used for PSB-36 (i.e., 10 Ϫ8 mol/l), it should only inhibit A1 receptors.
Statistics. Values are presented as means Ϯ SE. Single comparisons between normally distributed parameters were tested for significance with Student's paired or unpaired t-test. For the stop-flow pressure measurements, multiple groups were compared by one-way ANOVA. The Bonferroni posttest for paired multiple comparisons was used to allow for more than one comparison with the same variable. This states a significance level of P/M, where M is the number of comparisons to be made. Statistical significance was defined as P Ͻ 0.05.
RESULTS
All animals in this study were in good condition, and at the time of experiments there were no differences in body weights among the groups (Table 1 ). Blood pressure, heart rate, urine flow, P FF , and P SF (at 0 nl/min) were at a similar level.
Effect of adenosine A 2A receptor antagonist (ZM-241385).
The maximal control TGF response decreased P SF by 11.7 Ϯ 1.0 mmHg (P Ͻ 0.05) (Fig. 1A) . After intratubular pretreatment with a low dose of ZM-241385 (10 Ϫ7 mol/l), the maximal TGF response was clearly enhanced (15.7 Ϯ 0.8 mmHg) Values are means Ϯ SE. ATF, artificial tubular fluid; ZM, ZM-241385; PSB, PSB-36; MAP, mean arterial pressure; PFF, proximal free-flow pressure; PSF, proximal stop-flow pressure; m/n, animals and nephrons, respectively; M, mol/l. *P Ͻ 0.05 compared with PSF, at 0 nl/min, within each group (paired t-test). compared with control (P Ͻ 0.01) (Fig. 1B) . Pretreatment with a high dose of ZM-241385 (10 Ϫ5 mol/l) attenuated the maximal response (5.0 Ϯ 0.4 mmHg) compared with the control (P Ͻ 0.001) (Fig. 1C) . Examples of original recordings of P SF are shown in Fig. 2 .
Effect of adenosine A 1 receptor antagonist (PSB-36). After intratubular pretreatment with PSB-36 (10 Ϫ8 mol/l), an anomalous TGF response was observed with a paradoxical increase in P SF (Ϫ3.1 Ϯ 0.5 mmHg; P Ͻ 0.05) (Fig. 3A) . Examples of original recordings of P SF are shown in Fig. 4 .
Effect of adenosine A 1 ϩ A 2A receptor antagonists (PSB-36 ϩ ZM-241385).
After intratubular pretreatment with the combination of PSB-36 (10 Ϫ8 mol/l) and the lower concentration of ZM-241385 (10 Ϫ7 mol/l), the TGF response was abolished (0.4 Ϯ 0.3 mmHg) (Fig. 3B) . The maximal TGF response in the presence of both A 1 and A 2A receptor antagonists was significantly different from the response with A 1 receptor antagonist alone (P Ͻ 0.05). Examples of original recordings of P SF are shown in Fig. 4 .
A summary of the maximal TGF responses for the different adenosine receptor antagonists is shown in Fig. 5 . Inhibition of A 2 receptors enhanced the TGF response, and A 1 inhibition caused an abnormal TGF response, whereas A 1 ϩ A 2 inhibition abolished the TGF response. A 2 inhibition affected the TGF similarly, with or without inhibition of A 1 receptors.
DISCUSSION
In the present study, using the stop-flow technique to determine TGF, we show adenosine A 2 receptors modulate the responsiveness of TGF by counteracting the positive effect mediated by adenosine A 1 receptors.
Adenosine is an important paracrine agent regulating microvascular tone of the kidney via activation of A 1 and A 2 receptors. In contrast to the vasculature of most other organs, both A 1 and A 2 receptors are widely expressed in the preglomerular microcirculation (13, 34) . Studies in isolated and perfused renal afferent arterioles have demonstrated a biphasic response to adenosine, with contraction in the low concentration range and vasorelaxation at high concentration (5, 10, 17) . Vasoconstriction induced by adenosine is mediated via A 1 receptors, whereas vasodilatation by A 2 receptor modulates the response (5, 7, 10, 17) . The TGF mechanism is a negative feedback loop that enhances the vascular tone of the afferent arteriole when tubular NaCl delivery at the macula densa is increased (28) . Increased tubular flow rates are associated with increased adenosine formation in the juxtaglomerular apparatus (20, 23) . Studies in gene-deficient mice, or with receptor antagonists, have suggested that TGF is mediated via activation of adenosine A 1 receptors (4, 8, 29, 30) . However, studies have suggested that TGF signals are coupled to autoregulatory preglomerular vasoconstriction through ATP-mediated activation of P2X 1 receptors (12) . A direct role of ATP in mediating the TGF response may be possible, but the evidence for this is currently not compelling. Mice lacking P2X 1 receptors, which are present in vascular smooth muscle cells of afferent arteriole (6), display impaired preglomerular autoregulation (12) , but have largely normal TGF responses (27) . Furthermore, pharmacological inhibition of P2 receptors with suramin did not significantly inhibit TGF of microperfused afferent arterioles with attached macula densas (25) . The controversies regarding the role of adenosine or ATP as the signaling molecule may be because of regional differences of the kidney, since autoregulation studies were performed in juxtamedullary arterioles, whereas the TGF evidence comes from superficial nephrons.
Today, there is less information regarding the functional significance of A 2 receptors in TGF. Given the dilatory function of A 2 receptors in the afferent arteriole, we hypothesized that they might modulate TGF. In the present study, the role of A 2 receptors in regulation of TGF was studied by intratubular administration of potent and highly selective adenosine receptor antagonists. As previously shown by micropuncture experiments, an intraluminal delivery of adenosine analogs targets the vascular effector cells in the juxtaglomerular apparatus (8, 14, 26, 29) . The mechanisms for this are not clear, but access to the vascular receptor sites through permeable junctional complexes and intracellular pathways has been suggested (26) . In the experimental approach used in this and similar studies, the concentration of adenosine antagonists at the receptor site is unknown. However, it is reasonable to assume that concentrations at the receptor sites will be considerably lower than perfusate concentrations. To avoid substantial dilution and to allow time for transportation to the effector site, intratubular pretreatment was performed before the maximal TGF response was assessed. Pretreatment alone had no effect on P SF in any group.
Our findings demonstrate that A 2 receptors modulate TGF by counteracting the A 1 receptor-mediated contraction. Even though a potent and highly selective A 2A receptor antagonist was used (ZM-241385), the narrow window for receptor inhibition makes it difficult to rule out the possibility that also A 2B receptors contributed to our findings. Studies in isolated afferent arterioles showed that pretreatment with A 2A antagonist (ZM-241385; 10 Ϫ7 mol/l) caused a monophasic constrictor response to adenosine, which did not differ from combined A 2A and A 2B (MRS-1706; 10 Ϫ6 mol/l) receptor inhibition (17) . The authors therefore suggested a predominant role for A 2A receptors in adenosine-mediated dilatation of the arterioles.
Pretreatment with ZM-241385, at concentrations compatible with activation of A 2 receptors, enhanced the maximal TGF response, whereas at a high concentration the TGF response was attenuated compared with controls. This discrepancy is most likely because of nonspecific inhibition of adenosine receptors, including A 1 , at the high concentration (i.e., 10,000-fold higher than needed for A 2A activation). Studies have shown that preconstricted efferent arterioles dilate in response to increased macula densa NaCl, and in response to A 2 receptor activation (2, 24) . A possible efferent arteriole TGF may work in the opposite direction from that in afferent arterioles, thus modulating the glomerular filtration. Our results, however, indicate that the site of action is predominantly the afferent arterioles, since activation of adenosine postglomerular receptors would have the opposite result. However, it is possible that the effect observed with a much higher dose of ZM-241385 not only is mediated by inhibition of afferent A 1 receptors, but also inhibition of efferent A 2 receptors. Interestingly, inhibition of adenosine A 1 receptor, with a potent and selective antagonist (PSB-36; 10 Ϫ8 mol/l), was associated with an anomalous TGF response, where increased loop of Henle perfusion from 0 to 40 nl/min caused a negative change in P SF . The observed effect suggests A 2 receptor activation alone and is supported by the finding that cumulative application of adenosine in A 1 receptor-deficient mice is associated with a monophasic dilatory response (17) . In previous studies, A 1 receptor inhibition was not associated with a reversed TGF response (14, 29) . This discrepancy could be explained by the fact that the intratubular pretreatment used in the present study was more effective or by differences in the antagonists used.
Intraluminal administration of adenosine A 1 receptor analogs enhances TGF-mediated changes in P SF , an effect that is not dependent on the presence of a luminal NaCl signal (8, 26) . These findings are consistent with the concept that activation of A 1 receptors on vascular cells of the afferent arterioles participates in the mediation of the TGF responses, and has been confirmed by an abolished TGF in A 1 receptor-deficient mice (4, 30) . Given that specific A 1 receptor inhibition, in our study, was associated with a reversed TGF response, one would expect this to occur also in A 1 receptor-deficient mice. This was not systematically studied in A 1 -deficient mice. However, perfusion with the A 2 receptor agonist 5=-ethylcarboxamidoadenosine reduced or even reversed the TGF response at higher concentrations (26), supporting our finding that A 2 receptor activation may modulate the TGF response.
Although we interpret the effects of luminal perfusion of adenosine receptor antagonists as acting on the afferent arterioles, it is possible that intraluminal administration of these antagonists activated adenosine receptors located in thick ascending limb of Henle's loop and possibly on the macula densa cells (34) and, consequently, modified intracellular cAMP levels. In this regard, the A 2 receptor antagonist would decrease cAMP levels in the macula densa cells, thus enhancing the maximal TGF response. The A 1 receptor antagonist would increase cAMP levels in the macula densa cells, thus dilating afferent arterioles and attenuating the TGF response. However, if adenosine receptors located on macula densa cells would be the only site of action during intratubular administration, a revered TGF response during A 1 inhibition is not likely to occur. Considering that pretreatment was used and that adenosine analogs may access vascular cells in the juxtaglomerular apparatus, we find it unlikely that adenosine receptors located on macula densa cells would be the only target.
In conclusion, our findings demonstrate an important role of adenosine A 2 receptors in modulating the TGF response by counteracting adenosine A 1 receptor-mediated vasoconstriction. The mechanism responsible for A 2 receptor-mediated vasodilatation of afferent arterioles and its modulation of TGF is not clear. However, stimulation of A 2 receptors has been linked to release of nitric oxide (5, 10, 19, 22, 31) . Future studies may investigate the possible role of nitric oxide.
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